In contrast, using agonists to activate the cGAS-STING signaling pathway, thereby antagonizing the inhibitory signals of this pathway and reversing the immunosuppressive state, may be a more feasible approach, which is expected to break the resistance bottleneck of these tumor immunotherapies. This evidence concerns the gene STING1 and neoplasm.